Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study

INTRODUCTION: A twice-daily single inhaler triple therapy consisting of budesonide/glycopyrrolate/formoterol fumarate (BGF) was approved by the US Food and Drug Administration (FDA) in July 2020 as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). The objective...

Descripción completa

Detalles Bibliográficos
Autores principales: Portillo, Edward C., Pollack, Michael, Lee, Inyoung, Sun, Kainan, Zhao, Xiaohui, Kruse, Lisa, Feigler, Norbert, Patel, Sushma, Near, Aimee M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074608/
https://www.ncbi.nlm.nih.gov/pubmed/37013423
http://dx.doi.org/10.1177/17534666231164534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074608/
https://www.ncbi.nlm.nih.gov/pubmed/37013423
http://dx.doi.org/10.1177/17534666231164534

Ejemplares similares